Highlights in Resistance Mechanism Pathways for Combination Therapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Highlights in Resistance Mechanism Pathways for Combination Therapy
Authors
Keywords
-
Journal
Cells
Volume 8, Issue 9, Pages 1013
Publisher
MDPI AG
Online
2019-08-30
DOI
10.3390/cells8091013
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
- (2019) Giuseppe Curigliano et al. DRUG SAFETY
- Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
- (2019) Ariella B. Hanker et al. Cancer Discovery
- Synthetic lethality guiding selection of drug combinations in ovarian cancer
- (2019) Andreas Heinzel et al. PLoS One
- Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma
- (2019) Nicole L. Michmerhuizen et al. MOLECULAR PHARMACOLOGY
- A Code of Mono-phosphorylation Modulates the Function of RB
- (2019) Ioannis Sanidas et al. MOLECULAR CELL
- AKT as a Therapeutic Target for Cancer
- (2019) Mengqiu Song et al. CANCER RESEARCH
- Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers
- (2019) Masaru Katoh CLINICAL SCIENCE
- Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
- (2019) Sobhani et al. Cells
- Revisiting mTOR inhibitors as anticancer agents
- (2019) Qiu-Xu Teng et al. DRUG DISCOVERY TODAY
- Molecular mechanisms of anti-psychotic drugs for improvement of cancer treatment
- (2019) Narjes Hendouei et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
- (2018) Jordan Berlin et al. BRITISH JOURNAL OF CANCER
- Patient-derived organoid models help define personalized management of gastrointestinal cancer
- (2018) M. R. Aberle et al. BRITISH JOURNAL OF SURGERY
- A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer
- (2018) Michael J. Pishvaian et al. CANCER
- PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
- (2018) Anita A. Turk et al. CANCER
- ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
- (2018) Bijay S. Jaiswal et al. CLINICAL CANCER RESEARCH
- ALK inhibitors, resistance development, clinical trials
- (2018) J.M. Rothenstein et al. Current Oncology
- Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
- (2018) Chrysiis Michaloglou et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the PI3K pathway in cancer: are we making headway?
- (2018) Filip Janku et al. Nature Reviews Clinical Oncology
- Role of the NFκB-signaling pathway in cancer
- (2018) Longzheng Xia et al. OncoTargets and Therapy
- Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer.
- (2018) Neil Portman et al. ENDOCRINE-RELATED CANCER
- Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
- (2018) Martin J van den Bent et al. LANCET ONCOLOGY
- Recent developments in topoisomerase targeted cancer chemotherapy
- (2018) KirkE. Hevener et al. Acta Pharmaceutica Sinica B
- 1392PDose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
- (2018) A Santoro et al. ANNALS OF ONCOLOGY
- 852PPharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)
- (2018) A tripathi et al. ANNALS OF ONCOLOGY
- Randomized dose-escalation designs for drug combination cancer trials with immunotherapy
- (2018) Pavel Mozgunov et al. Journal of Biopharmaceutical Statistics
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma
- (2018) Xiaoxiong Wang et al. Cell Death & Disease
- Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
- (2018) Qingzhu Jia et al. Nature Communications
- A class of novel tubulin polymerization inhibitors exert effective anti-tumor activity via mitotic catastrophe
- (2018) Ya-Liang Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Clinical development of mTor inhibitors for renal cancer
- (2017) Michele Ghidini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer
- (2017) Shumei Kato et al. INVESTIGATIONAL NEW DRUGS
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Cell Cycle Control by PTEN
- (2017) Andrew Brandmaier et al. JOURNAL OF MOLECULAR BIOLOGY
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- The high price of anticancer drugs: origins, implications, barriers, solutions
- (2017) Vinay Prasad et al. Nature Reviews Clinical Oncology
- DrugBank 5.0: a major update to the DrugBank database for 2018
- (2017) David S Wishart et al. NUCLEIC ACIDS RESEARCH
- Dual role of autophagy in hallmarks of cancer
- (2017) Shikha Satendra Singh et al. ONCOGENE
- Inhibition of pRB Pathway Differentially Modulates Apoptosis in Esophageal Cancer Cells
- (2017) Rossana C. Soletti et al. Translational Oncology
- Repair, Reuse, Recycle: The Expanding Role of Autophagy in Genome Maintenance
- (2017) Graeme Hewitt et al. TRENDS IN CELL BIOLOGY
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- Tumor Evolution as a Therapeutic Target
- (2017) Nabil Amirouchene-Angelozzi et al. Cancer Discovery
- Combination therapy in combating cancer
- (2017) Reza Bayat Mokhtari et al. Oncotarget
- Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution
- (2017) Subramanian Venkatesan et al. Cold Spring Harbor Perspectives in Medicine
- A standard database for drug repositioning
- (2017) Adam S. Brown et al. Scientific Data
- The Complex Link between Apoptosis and Autophagy: a Promising New Role for RB
- (2016) JOÃO M.A. DELOU et al. ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
- mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells
- (2016) Ozge Berrak et al. APOPTOSIS
- Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
- (2016) P. M. Barr et al. BLOOD
- Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
- (2016) Andrew C. Wood et al. CLINICAL CANCER RESEARCH
- Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer
- (2016) N. A. Jabbour-Leung et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- The role of p53 in cancer drug resistance and targeted chemotherapy
- (2016) Karin Hientz et al. Oncotarget
- Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations
- (2016) Daphne Sun et al. Scientific Reports
- Approaches to modernize the combination drug development paradigm
- (2016) Daphne Day et al. Genome Medicine
- Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance
- (2015) Subburayan Karthikeyan et al. Anti-Cancer Agents in Medicinal Chemistry
- An essential role for Ink4 and Cip/Kip cell-cycle inhibitors in preventing replicative stress
- (2015) V Quereda et al. CELL DEATH AND DIFFERENTIATION
- ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
- (2015) Haigang Cui et al. CURRENT DRUG TARGETS
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Drug repurposing in oncology—patient and health systems opportunities
- (2015) Francesco Bertolini et al. Nature Reviews Clinical Oncology
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Coexpression of Multiple ABC-Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid Leukemia
- (2015) Stephan Bartholomae et al. PEDIATRIC BLOOD & CANCER
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1
- (2015) Wen-Ying Lee et al. Oncotarget
- Signal Transduction in Cancer
- (2015) R. Sever et al. Cold Spring Harbor Perspectives in Medicine
- PTEN: Multiple Functions in Human Malignant Tumors
- (2015) Michele Milella et al. Frontiers in Oncology
- Designs of drug-combination phase I trials in oncology: a systematic review of the literature
- (2014) M.- K. Riviere et al. ANNALS OF ONCOLOGY
- Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
- (2014) C. J. Paller et al. CLINICAL CANCER RESEARCH
- Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication
- (2014) David A. Nathanson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity
- (2013) Chirayu Patel et al. CANCER
- Autophagy and genomic integrity
- (2013) A T Vessoni et al. CELL DEATH AND DIFFERENTIATION
- Classification Models for Anticancer Activity
- (2013) R. Dutt et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
- (2013) Deepa Sampath et al. LEUKEMIA RESEARCH
- Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma
- (2013) Ralph J. Hauke et al. MELANOMA RESEARCH
- Nuclear Expression of β-Catenin Promotes RB Stability and Resistance to TNF-Induced Apoptosis in Colon Cancer Cells
- (2013) Jinbo Han et al. MOLECULAR CANCER RESEARCH
- Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs
- (2013) Geniey Yang et al. PHARMACOLOGY & THERAPEUTICS
- Cancer drug discovery by repurposing: teaching new tricks to old dogs
- (2013) Subash C. Gupta et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Retinoblastoma protein regulates the crosstalk between autophagy and apoptosis and favors glioblastoma resistance to etoposide
- (2013) D Biasoli et al. Cell Death & Disease
- ERK Pathway Inhibitors: How Low Should We Go?
- (2013) M. H. Nissan et al. Cancer Discovery
- Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis
- (2012) L. Ouyang et al. CELL PROLIFERATION
- A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer
- (2012) A. A. Secord et al. CLINICAL CANCER RESEARCH
- Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
- (2012) Alexander H Stegh EXPERT OPINION ON THERAPEUTIC TARGETS
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defining principles of combination drug mechanisms of action
- (2012) J. R. Pritchard et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- AMPK and mTOR coordinate the regulation of Ulk1 and mammalian autophagy initiation
- (2011) Libin Shang et al. Autophagy
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients
- (2011) C. Marzac et al. HAEMATOLOGICA
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Glutathione Transport Is a Unique Function of the ATP-binding Cassette Protein ABCG2
- (2010) Heather M. Brechbuhl et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Human Mutations That Confer Paclitaxel Resistance
- (2010) S. Yin et al. MOLECULAR CANCER THERAPEUTICS
- Mechanism matters
- (2010) NATURE MEDICINE
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Cancer Cells Acquire Mitotic Drug Resistance Properties Through Beta I-Tubulin Mutations and Alterations in the Expression of Beta-Tubulin Isotypes
- (2010) Chun Hei Antonio Cheung et al. PLoS One
- Anti- and pro-tumor functions of autophagy
- (2009) Eugenia Morselli et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers
- (2009) T. Tanei et al. CLINICAL CANCER RESEARCH
- SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions
- (2009) Saskia Preissner et al. NUCLEIC ACIDS RESEARCH
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
- (2008) J. N. Sarkaria et al. CLINICAL CANCER RESEARCH
- Elucidation of Different Binding Modes of Purine Nucleosides to Human Deoxycytidine Kinase
- (2008) Elisabetta Sabini et al. JOURNAL OF MEDICINAL CHEMISTRY
- Autophagic cell death: the story of a misnomer
- (2008) Guido Kroemer et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started